Published in

Royal Society of Chemistry, Organic and Biomolecular Chemistry, 7(14), p. 2318-2326, 2016

DOI: 10.1039/c5ob02630j

Links

Tools

Export citation

Search in Google Scholar

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters

Journal article published in 2016 by Petar O. Nikiforov, Sachin Surade, Michal Blaszczyk, Vincent Delorme ORCID, Priscille Brodin ORCID, Alain R. Baulard ORCID, Chris Abell, Tom L. Blundell
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial transcriptional repressor protein EthR is an attractive therapeutic strategy. Herein we report the use of a fragment based drug discovery approach for the structure-guided systematic merging of two fragment molecules, each binding twice to the hydrophobic cavity of EthR from M. tuberculosis. These together fill the entire binding pocket of EthR. We elaborated these fragment hits and developed small molecule inhibitors which have a 100-fold improvement of potency in vitro over the initial fragments.